Assessment of the efficacy and tolerability of melatonergic antidepressant treatment in patients surgical correction of the appearance

Close metadata

Recommended articles:

Sleep disorders and oncological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131

A perspective on the application of CRISPR/CAS9 genome editing system to study of molecular-genetic basis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33

Validation of screening method based on EEG analysis for the risk assessment of psychiatric and behavioral disorders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96

A clinical case of the new-onset bipolar affective disorder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129

Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74

Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79

Role of the dissection course on reconstructive maxillofacial surgery in the continuing medical education of maxillofacial surgeons. Russian Rhinology. 2024;(2):140-147

Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30

Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47

Objective. To study the efficacy and tolerability of agomelatine (valdoxan) in the treatment of affective disorders developed after surgical correction of the appearance. Material and methods. We summarized 35 cases characterized by the development of ICD-10 depressive disorders after the face surgery performed to correct congenital and acquired malformations. Agomelatine was prescribed in dose 25-50 mg daily during 6 weeks. Patient's state was assessed using psychopathological method and psychometric scales. Results and conclusion. We obtained significant results demonstrating the efficacy of this drug in mild and moderate depressive disorders. Agomelatine had a favorable tolerability profile that provided a high level of compliance of the patients.

Keywords:

plastic surgery

maxillofacial surgery

correction of the appearance

post surgery disorders

depression

agomelatine

Authors:

Medvedev V.E.

Peoples Friendship University of Russian

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Barsegian T.V.

GBOU VPO Moskovskiĭ gosudarstvennyĭ meditsinskiĭ stomatologicheskiĭ universitet im. A.I. Evdokimova, Moskva

List of references:

Medvedev V.E., Vissarionov V.A., Avdoshenko K.E., Martynov S.E. Rasprostranennost' psikhopatologicheskikh i patopsikhologicheskikh rasstroistv sredi patsientov plasticheskogo khirurga i kosmetologa (rezul'taty psikhometricheskogo issledovaniya). Psikhiatriya i psikhofarmakoterapiya 2011; 1: 18-22.
Shamov S.A. Osobennosti psikhicheskikh narushenii u bol'nykh zrelogo vozrasta s kosmeticheskimi defektami litsevoi oblasti. Patogenez, lechenie i profilaktika kosmeticheskikh zabolevanii i nedostatkov. M 1982; 165-170.
Valente S.M. Visual disfigurement and depression. Plast Surg Nurs 2009; 29: 1: 10-6; quiz 17-18.
Zatzick D.F., Russo J.E., Katon W. Somatic, posttraumatic stress, and depressive symptoms among injured patients treated in trauma surgery. Psychosomatics 2003; 44: 479-484.
Kheden P. Entsiklopediya plasticheskoi khirurgii. M 2001.
Rashid A., Brennen M.D. Psychiatric assessment of patients with self-inflicted lacerations to the wrist and forearm admitted to a nonpsychiatric ward: the experience of a regional plastic surgery unit. J Plast Reconstr Aesthet Surg 2006; 59: 3: 266-271.
Vissarionov V.A., Medvedev V.E., Avdoshenko K.E., Martynov S.E. Affektivnye i trevozhnye rasstroistva u patsientov plasticheskogo khirurga i kosmetologa. Eksperimental'naya i klinicheskaya dermatokosmetologiya 2011; 3: 60-64.
Medvedev V.E., Vissarionov V.A., Martynov S.E. Patokharakterologicheskie i patopsikhologicheskie rasstroistva u patsientov plasticheskogo khirurga i kosmetologa (rezul'taty psikhometricheskogo issledovaniya). Psikhiatriya i psikhofarmakoterapiya 2011; 6: 4-8.
Medvedev V.E., Frolova V.I., Barsegyan T.V. Terapiya nepsikhoticheskikh psikhicheskikh rasstroistv u patsientov, obrashchayushchikhsya za khirurgicheskoi korrektsiei vneshnosti. Rossiiskaya stomatologiya 2013; 4: 15-24.
Anderson R.C. Body dysmorphic disorder: recognition and treatment. Plast Surg Nurs 2003; 23: 3: 125-128.
Medvedev V.E., Barsegyan T.V., Frolova V.I. Patokharakterologicheskie i psikhopatologicheskie rasstroistva u patsientov s ostroi posttravmaticheskoi deformatsiei litsa (aspekty kliniki i terapii). Psikhicheskoe zdorov'e 2013; 7: 31-41.
Levine E., Degutis L., Pruzinsky T. Quality of life and facial trauma: psychological and body image effects. Ann Plast Surg 2005; 54: 502-510.
Medvedev V., Barsegyan T., Frolova V. Psychometric Evaluation of Psychopathologic Disorders in of Maxillofacial Surgeons' Patients. Psychotherapy and Psychosomatics 2013; 82: Suppl 1: 65.
Medvedev V., Frolova V., Martinov S., Vissarionov V. Mental Disorders and Personality Traits in Plastic Surgeons' and Cosmetologists' Patients. Psychotherapy and Psychosomatics 2013; 82: Suppl 1: 65.
Gol'dshtein Ya.N., Ganushkevich M.N. Znachenie plasticheskikh operatsii litsa dlya psikhicheskoi i sotsial'noi reabilitatsii. Act Chir Plastic 1980; 3: 121-124.
Marilova T.Yu., Malygin E.N. Rol' plasticheskikh operatsii na molochnoi zheleze v vosstanovlenii sotsial'no-psikhologicheskogo statusa bol'nykh. V kn.: Aktual'nye voprosy plasticheskoi khirurgii molochnoi zhelezy. M 1990; 6-7.
Biraben-Gotzamanis L., Aouizerate B., Martin-Guehl C. Body dysmorphic disorder and cosmetic surgery: assessment of 24 subjects with a minimal defect in appearance 5 years after their request for cosmetic surgery. Presse Med 2009; 38: 7-8: 1062-1067.
Sarver D.B., Infield A.L., Baker J.L. Two-year results of a prospective, multi-site investigation of patient satisfaction and psychosocial status following cosmetic surgery. Aesthet Surg J 2008; 28: 3: 245-250.
Baranskaya L.T. Faktory riska rasstroistv lichnostnoi adaptatsii u patsientov esteticheskoi khirurgii. Ekaterinburg 2009.
Rohrich R.J. The who, what, when and why of cosmetic surgery: do our patients need a preoperative psychiatric evaluation? Plast Reconst Surg 2000; 106: 1605-1607.
Medvedev V.E., Barsegyan T.V., Drobyshev A.V. Terapiya depressivnykh i trevozhnykh rasstroistv u patsientov, obrashchayushchikhsya za khirurgicheskoi korrektsiei vneshnosti. Psikhicheskoe zdorov'e 2012; 5: 72: 40-45.
Bochkarev M.V., Ragozin O.N., Frosin S.A. Primenenie val'doksana u bol'nykh serdechno-sosudistymi zabolevaniyami s narusheniyami sna i depressiei v usloviyakh Severnogo regiona Rossii. Psikhicheskie rasstroistva v obshchei meditsine 2012; 4: 69-74.
Medvedev V.E., Chobanu I.K., Frolova V.I., Zuikova N.L., Epifanov A.V. Effektivnost' psikhofarmakoterapii i psikhoterapii u patsientov s serdechno-sosudistymi zabolevaniyami. Arkhiv vnutrennei meditsiny 2013; 5: 61-66.
Statsenko M.E., Shilina N.N. Vliyanie terapii val'doksanom na techenie vosstanovitel'nogo perioda u bol'nykh s infarktom miokarda s sopustsvuyushchimi sakharnym diabetom tipa 2 i affektivnymi rasstroistvami. Psikhiatriya i psikhofarmakoterapiya 2013; 5: 16-20.
Loo H., Hale A., D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247.
Millan M.J., Gobert A., Lejeune F. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydro-xytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
Olie J.P., Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661-673.
Audinot V., Mailliet F., Lahaye-Brasseur C. New selective ligands of human cloned melatonin MTI and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 553-561.
Antokhin E.Yu. Terapiya tyazheloi rekurrentnoi depressii. Psikhiatriya i psikhofarmakoterapiya 2010; 6.
Medvedev V.E. Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression. Neuroscience and Behavioral Physiology 2013; 7: 43: 878-882.
Crerand C.E., Franklin M.E., Sarwer D.B. Body dysmorphic disorder and cosmetic surgery. Plast Reconstr Surg 2006; 118: 7: 167-180.
Ferraro G.A., Rossano F., Andrea F. Self-perception and self-esteem of patients seeking cosmetic surgery. Aesthetic plast Surg 2005; 3: 184-189.
Tignot J., Biraben-Gotzamanis L., Martin-Guehl C. Body dysmorphic disorder and cosmetic surgery: evolution of 24 subjects wit. Eur Psychiat 2007; 22: 8: 520-524.
Vindgni V. The importance of recognizing body dismorphic disorder in cosmetic surgery patients: do our patients need a preoperative psychiatric evaluation? Eur J Plast Surg 2002; 25: 305-308.
Medvedev V.E., Gushanskaya E.V., Ter-Israelyan A.Yu. Terapiya depressii s yavleniyami angedonii (opyt primeneniya val'doksana). Psikhiatriya i psikhofarmakoterapiya 2014; 3: 35-49.

Close metadata